Invizyne (EXOZ) - Gross Profitability Margin

Official company branding of Invizyne Technologies, Inc. (EXOZ)

High barriers to entry in the sector are driven by synthesis patents and the complexity of scaling technologies. The gross margin chart illustrates current trends, where the metric level stands at 0.00. eXoZymes Inc (EXOZ) bases its growth on reducing costs associated with the creation of complex molecules. Business stability is ensured through the diversification of raw material streams and the optimization of inventory to eliminate disruptions.

Gross Profitability: eXoZymes (EXOZ) for 02/13/2025 - 11/20/2026

Analytical breakdowns and data insights for company invizyne.com (EXOZ)

- stock value and consensus price forecast:
Summary company analysis:eXoZymes (EXOZ)
Signature product of eXoZymes Inc

Investors utilize this indicator for comparative asset analysis to evaluate the efficiency of direct cost management and the business's ability to convert revenue into operating profit. The calculation model subtracts the cost of goods sold from total revenue, which in the case of eXoZymes Inc (EXOZ) reflects the savings derived from the cell-free synthesis of complex molecules, and this trend is clearly illustrated in the projected gross margin.

Direct competitors

Gross Profit Margin Haleon PLC (HLN)|Return on Gross Profit KVUE|Gross Profit Margin Verona Pharma Inc. VRNA|Gross Margin MENS|Ligand Pharmaceuticals - Gross Return on Sales|Gross Profitability Amneal AMRX|Gross Sales Margin Perrigo Company PLC|Alvotech Biopharmaceuticals - Gross Margin|Return on Sales by Gross Profit Liquidia Technologies LQDA|Galapagos N.V. (GLPG) - Gross Profitability|anipharmaceuticals.com - Gross Profit Rate|Return on Gross Profit MNKD|AMPH: Gross Profit Rate|Gross Profitability pacira.com (PCRX)|Gross Margin ARS Pharma (SPRY)|Theravance Biopharma - Return on Gross Profit|Gross Profit Ratio AQST (Aquestive Therapeutics)|SCPH: Return on Gross Profit|Gross Profit Margin Tectonic Therapeutic|TNXP: Gross Margin|SXT China (SXTC) - Gross Margin|Gross Profitability eupraxiapharma.com|BioHarvest Sciences (BHST) - Return on Sales by Gross Profit|Gross Margin ORMP|Return on Sales by Gross Profit Entera Bio|Gross Margin HYFT (MindWalk Holdings, Inc.)|ABVC BioPharma - Gross Profitability|Cumberland Corp - Gross Margin|QNTM - Gross Margin|FibroGen, Inc. (FGEN) - Gross Profitability|TELO: Gross Profit Ratio|RANI (Rani Therapeutics Inc) - Gross Margin|Gross Profit Margin synergychc.com SNYR|Gross Profitability Rallybio Corp. (RLYB)|LEXX - Gross Profit Margin|Gross Margin PULM (pulmatrix.com)|Gross Profit Ratio PTHL (Pheton)|APM - Gross Profitability|Return on Sales by Gross Profit Lyra Therapeutics Inc LYRA|impactbiomedinc.com (IBO) - Gross Profitability|TNF Pharma (TNFA) - Gross Margin|YCBD (cbdmd.com) - Gross Margin|Return on Gross Profit PainReform (PRFX)|Gross Profitability Altamira Therapeutics (CYTO)|Return on Sales by Gross Profit Lipella Pharma|Optinose - Return on Gross Profit|Return on Sales by Gross Profit pieris.com (PIRS)|PROC - Gross Profitability|Gross Profitability Margin PTPI|QLI: Gross Margin|Gross Profit Margin ACELYRIN Inc. (SLRN)|TFFP (TFF Pharmaceuticals, Inc) - Gross Margin